HUTCHMED’s ORPATHYS and TAGRISSO Accepted for Regulatory Review
HUTCHMED said filings for ORPATHYS and AstraZeneca’s TAGRISSO were accepted for regulatory review in Europe and Japan.
Related stories
Unigroup Guoxin plans share buyback
Unigroup Guoxin said it plans to repurchase company shares for 5–7亿元.
M impact | EQUITY | Nov 02, 2026, 11:22 AM UTC
Escorts Kubota Q2 Profit Falls to ₹250 Crore
Escorts Kubota reported a fall in second-quarter profit as rising commodity costs and an unfavourable product mix squeezed tractor margins, outweighing strong construction equipmen
M impact | EQUITY | Nov 02, 2026, 11:22 AM UTC
VRL Logistics Q2 Profit More Than Doubles to ₹103 Crore
VRL Logistics reported Q2 FY27 profit after tax of ₹103 crore, up from ₹50 crore a year earlier. Revenue rose 20.7% year on year, and EBITDA margin expanded to 23%.
M impact | EQUITY | Nov 02, 2026, 11:22 AM UTC
Tesla sales in Spain rise 271% year-on-year in October
M impact | EQUITY | Nov 02, 2026, 11:21 AM UTC
Estee Lauder Reports Higher Fiscal Q1 Adjusted Earnings and Sales
M impact | EQUITY | Nov 02, 2026, 11:20 AM UTC
Granules India Reports Q2 Consolidated Revenue of 15.6 Billion Rupees
M impact | EQUITY | Nov 02, 2026, 11:20 AM UTC